{Reference Type}: Journal Article
{Title}: Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer.
{Author}: El Kaddissi A;Vernerey D;Falcoz A;Mansi L;Bazan F;Chaigneau L;Dobi E;Goujon M;Meneveau N;Paillard MJ;Selmani Z;Viot J;Molimard C;Monnien F;Woronoff AS;Curtit E;Borg C;Meynard G;
{Journal}: Clin Breast Cancer
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 19
{Factor}: 3.078
{DOI}: 10.1016/j.clbc.2024.06.006
{Abstract}: OBJECTIVE: Eribulin is used in taxane and anthracycline refractory HER2-negative metastatic breast cancers (MBC). Patients treated in pivotal clinical trials achieved low survival rates, therefore, the identification of prognostic criteria for long progression-free survival (PFS) is still an unmet medical need. In this study, we sought to determine potential prognostic criteria for long-term eribulin response in HER2-negative MBC.
METHODS: Our retrospective cohort includes female patients with HER2-negative MBC treated with eribulin in Franche-Comté, France. We defined a long-term response as at least 6 months of eribulin treatment. The primary endpoint was the analysis of criteria that differ according to the progression-free survival. Secondary outcomes concerned overall survival and response rate.
RESULTS: From January 2011 to April 2020, 431 patients treated with eribulin were screened. Of them, 374 patients were included. Median PFS was 3.2 months (2.8-3.7). Eighty-eight patients (23.5%) had a long-term response to eribulin. Four discriminant criteria allowed to separate PFS in 2 arms (PFS < 3 months or > 6 months) with a 78% positive predictive value: histological grade, absence of meningeal metastasis, response to prior chemotherapy, and OMS status. We have developed a nomogram combining these 4 criteria. Median overall survival was 8.5 months (7.0-9.5).
CONCLUSIONS: Eribulin response in MBC can be driven by clinical and biological factors. Application of our nomogram could assist in the prescription of eribulin.